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Available online 10 February 2016Aims: Endothelin-1 levels are raised in chronic thromboembolic pulmonary hypertension. Our aim in this study
was to identify the presence of endothelin receptors in patients with CTEPH by analysing tissue removed at pul-
monary endarterectomy.
Main methods: Pulmonary endarterectomy tissue cross-sections were analysed using autoradiography with
[125I]-ET-1 using ligands selective for ETA or ETB to determine sub-type distribution. The precise cellular
localisation of ETA and ETB receptors was determined using selective antisera to both sub-types and compared
with haematoxylin and eosin, Elastic Van Gieson and smooth muscle actin labelled sections.
Key ﬁndings: Two patterns of ET-1 binding were found. In sections with frequent recanalised channels, ET-1
bound to the smooth muscle cells surrounding the channels. In sections where there was less organised throm-
bus with no obvious re-canalisation, minimal ET-1 binding was observed. Some contractile type smooth muscle
cells not associatedwith recanalised channels and diffusely spread throughout the PEAmaterial were associated
with ET receptor antibody binding on immunohistochemistry. Therewas a greater expression of the ETA receptor
type in the specimens.
Signiﬁcance: The presence of ET-1 receptors in the chronic thrombus in proximal CTEPH suggests ET-1 could act
not only on the distal vasculopathy in the unobstructed vessels but may also stimulate smooth muscle cell pro-
liferationwithin chronic clot. The abundance of ET receptorswithin the tissue provides evidence that the ET path-
way is involved in the pathology of chronic thrombus reorganisation leading to CTEPH providing a rationale for
the repurposing of ET receptor antagonists in the treatment of this condition.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Pulmonary endarterectomy1. Introduction
At present there is a limited understanding of the factors responsible
for failure of resolution of acute pulmonary embolism and the subse-
quent development of chronic thromboembolic pulmonary hyperten-
sion (CTEPH). The raised pulmonary vascular resistance (PVR) in
CTEPH is described by a two compartment model [20]. In some regions
there are thromboembolic occlusions of the vascular lumen and a series
of associated changes including clot remodelling, collagen deposition
and cellular hyperplasia. The ‘closed’ arterial tree distal to these obstruc-
tions is spared from exposure to high pressures. In other regions thend Therapeutics, University of
110, Addenbrooke's Hospital,
nport).
. This is an open access article under‘open’ arterial tree is exposed to high pressures and demonstrates path-
ological changes similar to those seen in pulmonary arterial hyperten-
sion (PAH); a distal vasculopathy with muscularisation of the distal
precapillary arteries and intimal hyperplasia with medial hypertrophy
of some larger pulmonary arteries [20]. Currently, CTEPH is the only
form of pulmonary hypertension for which there is a potential cure;
pulmonary endarterectomy (PEA), through the surgical removal of
proximal chronic thromboembolic material [22].
Endothelin-1 (ET-1) is a potent vasoconstrictor. High levels of circu-
lating ET-1 or its precursor big ET-1 have been demonstrated in patients
with idiopathic PAH [9, 15, 29]. The ET pathway is considered an impor-
tant part of the pathology of idiopathic PAH and ET receptor antagonists
such as bosentan and ambrisentan [17, 18] and more recently
macitentan [7] are used to try to slow progression. To date there is no
ET antagonist licenced for use in CTEPH patients, although they are
used ‘off-label’. The BENEFIT study did show a signiﬁcant haemody-
namic improvement with reduction in PVR, but no functional improve-
ment with bosentan [11]. ET-1 acts via two receptors, ETA and ETB,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cells. The ETA receptor activation results in vasoconstriction and smooth
muscle cell proliferation. The ETB receptor activation prevents apoptosis
of smoothmuscle cells and causes vasodilatation via nitric oxide stimu-
lation. ET-1 is a potent vasoconstrictor but is also a promoter of pulmo-
nary artery smooth muscle cell proliferation [8]. In agreement, Quarck
et al. [5] found that pulmonary arterial smooth muscle cells isolated
from patients with CTEPH have enhanced proliferative properties.
In patients with CTEPH, ET-1 levels are raised and have been shown
to fall after PEA surgery [24]. After an acute pulmonary embolism there
is obstruction of thepulmonary arteries by acute thrombus and elevated
levels of ET-1 [28, 30]. Elevated levels of ET-1 have also been observed in
air embolus in animal models [25, 26] and pretreatment with an ET an-
tagonist ameliorated the haemodynamic change after acute pulmonary
embolism [25]. In addition ET-1 is increased most in the muscularised
pulmonary arteries [16]. Intriguingly in human coronary arteries we
have previously shown that recanalisation of thrombus is characterised
by formation of new vesselswhich show intense endothelial ET-like im-
munoreactivity with ETA but not ETB receptors on the smoothmuscle of
recanalised vessels [2]. Crucially, ET antagonists have been shown to
block proliferation of smooth muscle in the intimal layer of vessels
growing in organ culture [19]. The pathogenesis of CTEPH is complex
but one question that arises is how much of the disease progression is
driven by changes within the unresolved thrombus in parallel to the
vasculopathy in the distal arterial bed. Despite many centres offering
off-label use of ET receptor antagonist in the treatment of CTEPH, little
is understood concerning the presence and underlying pattern distribu-
tion of ET receptors within PEA material. Here we identify ET receptors
in PEA material and provide a rationale for the ET receptor antagonists
for treatment of CTEPH.
2. Material and methods
2.1. Human tissue samples
Human tissues were obtained with informed consent from the
Papworth Hospital Research Tissue Bank (REC 08/H0304/56) and local
approval (REC 05/Q0104/142). Tissue specimens were collected from
consecutive patients undergoing PEA surgery for analysis. Information
was collected prospectively based on factors that were considered rele-
vant to the interpretation of the histological appearance and any ET re-
ceptor pattern. This included the use and type of targeted therapy forFig. 1. (A) Typical PEAmaterial Example of a PEA surgical specimen from the left lung of a patie
indicated with dashed lines. (B), Typical ﬁndings of H&E stained proximal PEA material. (C) T
neovessels (scale bars = 100 μm).pulmonary hypertension prior to surgery, haemodynamics from at the
time of diagnosis, the intraoperative macroscopic surgical assessment
of the type of chronic thromboembolic pulmonary arterial obstruction
[12] and follow up post-operative haemodynamic measurements from
assessment at least 3–6 months after PEA surgery. None of the patients
had prior treatment with an ET receptor antagonist (to avoid the possi-
ble inﬂuence on ET receptor expression) [10].
During the PEA surgery the tunica intima and a superﬁcial layer of
tunica media was removed along with the luminal contents. This tissue
was thenpreserved in ice cold Krebs solution. Cross-sectionswere taken
from the main endarterectomy cast, normally one from the most prox-
imal portion and other samples from smaller,more distal portions of the
PEA material [Fig. 1]. These samples were kept at−80 °C and batched
for autoradiographical analysis and confocal microscopy. Serial 10 μm
sections were cut using a cryostat. Adjacent formalin ﬁxed parafﬁn
wax embedded blocks were taken for routine histological examination
and immunohistochemistry. To determine the precise type of cell ex-
pressing the ET receptors, immunohistochemistry was performed to
characterise the cell types that showed strong expression of the ET re-
ceptor in the ligand binding assays.2.2. Autoradiography
Autoradiography was carried out using established techniques [6,
13]. Brieﬂy, sections were pre-incubated for 20 min at 23 °C in assay
buffer (50mMHepes, 5mMMgCl2, 0.3% BSA, pH 7.4) prior t, California)
to determine the distribution of all ET receptors. ET receptor subtypes
were visualised by incubating adjacent sections with [125I]-ET-1
(0.1 nM) alone to measure total binding, and in the presence of either
0.2 μMBQ3020 (to detect ETA) orwith 0.1 μMBQ123 (to detect ETB). Re-
ceptor occupancy curves based on the known speciﬁcity of each com-
pound were used to determine the concentration of each ligand. Non-
speciﬁc binding was deﬁned by incubating a further adjacent section
with the radioligand in the presence of 1 μM unlabelled ET-1 (Peptide
Institute, Osaka, Japan).
Following incubation the sections were washed (3 × 5 min) in ice-
cold Tris-HCl buffer (50 mM, pH 7.4), air dried and apposed, together
with [125I]-ET-1 standards, to Kodak MR-1 autoradiography ﬁlm for
3 days at room temperature. The ﬁlmswere processed and resulting au-
toradiograms photographed (Wild Heerbrugg microscope with Optim
digital camera and Pixel Link OEM software).nt with CTEPH. Cross-sections taken from the central proximal and distal tail portions are
ypical ﬁndings of H&E stained distal PEA material, being highly organised with frequent
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The degree of ET binding was assessed independently by two indi-
viduals and graded on the appearance of the autoradiogram alone.
Broadly this was grouped into the following groups: none, b25%, 25%–
50%, 50%–75%, N75%. Datawere analysed usingGraphPad Prism and dif-
ference between groupswere assessed using a Student's t-test. A p value
of b0.05 was considered signiﬁcant.2.4. Histopathology, immunohistochemistry and confocal microscopy
Slides were prepared from cutting sections from each 4 μmwax em-
bedded tissue block. After 48 h in the oven to melt the wax and dry the
tissue, the slides were put in PTmodules (Dako Ltd, UK) for 1 h at 98 °C
for antigen retrieval. After washing (with PBS solution) the slides were
exposed to hydrogen peroxidase 3% blocking solution (Dako Ltd, UK)
before being washed again with PBS. The primary antibody incubations
were all for one hour at room temperature. Immunolabelling was per-
formed using polyclonal rabbit anti-human ETA receptor antibody
(ab84673, Abcam plc, Cambridge, UK); polyclonal rabbit anti-human
ETB receptor antibody C– terminal (ab84182, Abcam plc, Cambridge,
UK), monoclonal mouse anti-human smooth muscle actin (Dako Ltd,
UK) andmonoclonal mouse anti-human CD31 (Dako Ltd, UK). Negative
controls were incubated with EnVision Flex antibody diluent alone. Tis-
sue sections were washed and incubated for 30 min with goat anti-
mouse/rabbit secondary antibodies EnVision Flex HRP (Dako Ltd, UK),
washed and labelled using Flex DAB+ Chromogen (Dako Ltd, UK),
washed and counter stained with Haematoxylin. The stained tissue sec-
tionswere examined by a histopathologistwith a special interest in pul-
monary hypertension (MG). A brief description of the histological
appearance for each section was made based on the degree of obstruc-
tion of the vessel lumen, the presence of smoothmuscle cells within the
pulmonary artery lumen, the presence of endothelialised and
recanalised channels with distinct organisation of smooth muscle cells
surrounding these new channels. Serial frozen sections were also used
for co-localisation studies using polyclonal rabbit anti-human ETA or
polyclonal rabbit anti-human ETB receptor antibody C-terminal
(ab84182, Abcam plc, Cambridge, UK), incubated with goat anti-rabbit
IgG conjugated Texas red (red). Cytoskeletal actin ﬁlaments [27] were
labelled using alexa488 (green) conjugated phalloidin (Invitrogen,
UK) and nuclei labelled using 4′,6-diamidino-2-phenylindole (DAPI;
blue).Table 1
Patient demographics.
Case Surgical
classiﬁcation
Pre-PEA drug therapy Pre-PEA mPAP (mm Hg) Pre-PE
Right Left
1 1 2 Sildenaﬁl 55 794
2 1 1 None 50 816
3 1 1 None 47 908
4 2 3 Sildenaﬁl 43 1162
5 1 2/3 None 29 315
6 2 3/4 Sildenaﬁl 50 831
7 1 2 None 53 733
8 2 2 None 33 286
9 3 3 Sildenaﬁl 74 1561
10 2 2 None 33 297
11 1 2 Sildenaﬁl 43 491
12 2 2 Sildenaﬁl 44 1053
13 1 1 Sildenaﬁl 43 880
14 2 2 None 28 222
15 1 1 Sildenaﬁl 47 888
16 1 2 Sildenaﬁl 60 1274
17 1 1 Sildenaﬁl 45 475
18 2 2 None 31 400
19 2 3 None 50 15043. Results
Pulmonary endarterectomy specimens from 19 patients were col-
lected; 14male, 5 female. Themean agewas 63±9.7 years. One patient
died in hospital and another patient did not return for post-operative
follow-up. Table 1 shows the severity of the pulmonary hypertension
and includes the surgical disease type (from the classiﬁcation by [12]),
haemodynamics at the time of initial diagnosis and any pre-operative
drug treatment. The haemodynamic variables demonstrate reasonably
severe pulmonary hypertension (pulmonary vascular resistance
763 ± 377 dyn·s·cm−5). Ten patients had received pre-operative
drug treatment with a phosphodiesterase V inhibitor, sildenaﬁl, prior
to PEA surgery. Mean pulmonary artery pressure (mPAP) was higher
(p=0.024) in the sildenaﬁl treated group (50.90± 9.92 mmHg) com-
pared to patients not on therapy (39.33± 10.36mmHg). PVRwas sim-
ilar between both groups. Pre-operative drug treatment did not appear
to have any signiﬁcant effect on ET receptor expression (data not
shown). The majority of cases were Jaimeson classiﬁcation type 1 or
type 2. A typical example of a PEA specimen is included in Fig. 1A.
§ = died following PEA surgery. # = did not return for follow-up.
3.1. Histopathology of PEA material
Forty three samples of tissue were taken for examination. Micro-
scopically, the histological specimens were found to contain regions of
fresh thrombus, intimal ﬁbrosiswith some degree ofmedial hyperplasia
and organised thrombus in keeping with previous reports [4, 23]. We
observed overall appearance, approximate vessel dimensions, the de-
gree of luminal obstruction and the number of recanalised channels.
Proximal PEA material was comprised predominantly of matrix-rich ﬁ-
brous tissue with little evidence of recanalization (Fig. 1B). The approx-
imate size of the native vessels examined ranged between about 40mm
and 5 mm in diameter. 6 sections were either fragments, long strips of
tissue or had no discernible intimal layer. For the remaining thirty
seven sections the degree of occlusion of the lumen of the native pulmo-
nary artery was b50% in 8 specimens, N50% in 8 specimens, 100% oc-
cluded in 21 specimens. Unsurprisingly the smaller diameter tissue
specimens displayed more intraluminal obstruction than the larger
specimens. Fresh thrombus comprised ﬁbrous tissue and loose
ﬁbromyxoid tissue with little evidence of organisation or matrix com-
ponents. In more distal PEA material frequent recanalised channels
were observed in many specimens, particularly evident in those of a
smaller size (Fig. 1C). We next sought to the cell morphologies and toA PVR (dyn·s·cm−5) Post-PEA mPAP (mm Hg) Post-PEA PVR (dyn·s·cm−5)
26 218
17 146
25 156
37 549
25 202
32 515
24 151
21 221
§ §
27 204
38 304
19 163
29 382
20 166
43 545
50 702
22 126
# #
42 1002
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material.
3.2. Autoradiographical ET receptor binding in PEA material
Recent proximal thrombuswith little evidence of neovascularization
demonstrated no obvious pattern of expression for ETA or ETB receptors.
In contrast, the autoradiograms showed ET binding was present in the
majority of the distal pulmonary endarterectomy cross-sections. Spe-
ciﬁc ET receptor binding was observed in 32 of the 43 specimens. Auto-
radiography showed that ETA predominated; all thirty two specimens
express this sub-type. ETB binding was detected in twenty eight speci-
mens and was more limited within the organised thrombus where
ETB receptors co-localizedwith ETA receptors in all but one case. The tis-
sue specimens with 100% occlusion showed the greatest proportion of
ET receptor binding. These specimens were generally smaller in diame-
ter and displayed a greater number of recanalised channels and a higher
degree thrombus organisation.We estimated the % of the PEA specimen
area to be either total ET, ETA or ETB positive in organised (predomi-
nantly proximal) and non-organised (predominantly distal PEA mate-
rial. We found signiﬁcantly higher levels of total ET and ETA receptors
in organised PEA material compared to non-organised PEA material
(Fig. 2A). A highly organised PEA specimen is also included in Fig. 2
where total ET (B and C), ETA (D), ETB (E) are summarised. Serial stain-
ing of adjacent sectionswith H&E (F), SMA (G) and CD31 (H) suggested
that ETB receptors were predominantly colocalised to areas also
displaying SMA immunostaining.
3.3. Immunohistochemistry and confocal characterisation of ET receptors in
PEA material
To further understand the distribution of ET receptors in PEA mate-
rial, we performed immunohistochemistry for ETA and ETB receptors
with anti-human SMA-α (to label smooth muscle cells and
myoﬁbroblasts) and anti-human CD31 to identify endothelial cells.
Basal levels of ETA and ETB expression were observed in regions popu-
lated with secretory SMCs distributed throughout the non- or loosely-
organised regions of ﬁbromyxoid connective tissue in the proximal ma-
terial (Fig. 3A–D).Fig. 2.We estimated the % of the PEA specimen area to be either total ET, ETA or ETB positiv
material. We found signiﬁcantly higher levels of total ET and ETA receptors in organised PEA
is also included in this ﬁgure where total ET (B and C), ETA (D), ETB (E) are summarised. Seri
receptors were predominantly colocalised to areas also displaying SMA immunostaining (scaleThe distal, smaller samples of PEAmaterial commonly contained fre-
quent recanalised neovessels surrounded by looseﬁbromyxoid tissue as
demonstrated by H&E (Fig. 3E). An Elastic Van Gieson stain (Fig. 3F)
demonstrates diffuse collagen (red) surrounded by elastin ﬁbres
(black). Immunohistochemistry revealed strong levels of ETA (Fig. 3G)
receptors and the presence of ETB (Fig. 3H) to be expressed by the
neovessels. Neovessel throughout the distal PEAmaterial each recapitu-
lated thehistological architecture of an artery, beinghaving a contractile
ring of SMA-α positive fusiform myoﬁbroblasts (Fig. 3I) with an
endothelialised CD31-positive lumen (Fig. 3J). Co-localisation studies
using confocalmicroscopy conﬁrmed ETA and ETB expression to be asso-
ciated with Actin ﬁlaments in the muscularised portion of the
recanalised vessel (Fig. 4).
4. Discussion
CTEPH is caused by chronic thromboembolic obstruction of the pul-
monary vasculature and the more distal portions of this residual mate-
rial can completely occlude the lumen and have been shown to contain
frequent newly formed vascular channels [1, 31]. Our results show that
ET receptors are present within the luminal obstructions removed from
pulmonary artery branches during PEA surgery for patients with CTEPH.
To our knowledge this is the ﬁrst time this has been shown using auto-
radiography. A crucial advantage of using autoradiography to identify
ET receptors is that the receptor must be expressed on the cell surface
and functionally viable for the radiolabelled ET ligand to bind. This pro-
vides mechanistic evidence for circulating ET to play a role in the
organised thrombus present in the larger pulmonary vessels. This
novel observation implies that ET receptor antagonists could act on
thepulmonary circulation in CTEPHat the level of the organising throm-
bus as well as in the small-vessel arteriopathy. Analysis of the distribu-
tion of the ET receptors in the specimens shows that the larger less
occluded pulmonary arteries (N14mmdiameter) had fewer recanalised
channels present and a lower expression of ET receptors, in contrast to
the smaller specimens.
4.1. PEA specimen histology
The heterogeneous nature of the pulmonary endarterectomy speci-
mens from our patient cohort is unsurprising. Macroscopically thee in organised (predominantly distal) and non-organised (predominantly proximal PEA
material compared to non-organised PEA material (A). A highly organised PEA specimen
al staining of adjacent sections with H&E (F), SMA (G) and CD31 (H) suggested that ETA
bar = 0.5 mm).
Fig. 3. PEA histopathology and ET receptor expression. Representative images of the histopathology commonly observed in PEAmaterial. Proximal PEAmaterial are collagen rich (B) with
little obvious pattern of (C) ETA or ETB (D) receptor expression. Distal PEA material tends to be more organised with the presence of frequent recanalised neovessels (E) surrounded by
looseﬁbromyxoid tissue as demonstrated byH&E. AnElastic VanGieson stain (F) demonstrates diffuse collagen (red) surrounded by elastinﬁbres (black). Immunostaining for ETA (G) and
ETB (H) reveal vascular expression of both receptor types. Neovessels present in distal PEA material each recapitulating the histological architecture of an artery, having arranged
contractile SMA-positive (fusiform) SMCs (I) and an endothelialised CD31 positive lumen (J). Arrows demonstrate an endothelial cell lined neovessel surrounded by organised SMCs.
Scale bars in A–D = 100 μm. Scale bars in E–J = 50 μm.
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surgery (using the classiﬁcation from Jaimeson). To overcome the het-
erogeneity of the tissue, it would have been desirable to use a greater
number of cross-sections from the same patient. This would have po-
tentially allowed for a more systematic analysis of the surgical tissue
based on anatomical location. This was not possible to perform as the
bulk of the extracted tissue was required for histological analysis for
the patient and could therefore not be sent away for autoradiography.
The histopathological appearance of the cross-sections through our
PEA specimens is consistent with previous studies [1, 4, 31] frompathological descriptions of CTEPH arising from post-mortem examina-
tions, lung transplantation or from lung biopsies.
4.2. ET receptor distribution ETA vs ETB
The ETA receptor activation results in vasoconstriction and smooth
muscle cell proliferation. The ETB receptor is located in the endothelium
and its activation prevents apoptosis of smooth muscle cells and causes
vasodilatation via release of nitric oxide. The pattern of ETA and ETB re-
ceptor distribution in the lung has been previously demonstrated in
Fig. 4. ETA receptors are expressed by neovessels in PEAmaterial. To conﬁrm the vascular expression of ETA in distal PEAmaterial we undertook confocal microscopy. (A) Cell nuclei were
labelled using 4′,6-diamidino-2-phenylindole (DAPI; blue). (B) Cytoskeletal actin ﬁlaments were labelled using alexa488 (green) conjugated phalloidin and (C) immunostained with
polyclonal rabbit anti-human ETA labelled with Texas red (red). Co-localisation studies conﬁrmed strong ETA expression to be associated with Actin ﬁlaments in the muscularised
portion of the recanalised vessel (D). Scale bars = 25 μm.
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ease and idiopathic pulmonary hypertension subjects the larger calibre
vessels showed predominant ETA expression with a relative increase in
the ETB expression as the vessels narrow to 0.5-1 mm diameter (while
remaining b50% overall expression at this size). In the main pulmonary
arteries N90% of ET expression demonstrated in the medial layer is ETA
receptor. ETB vascular expression is seen to a lesser degree in the small
conduit arteries but at lower levels than seen for ETA. Within the rest of
the lung ETA expression is found in the parenchyma, airway smooth
muscle and epithelial cells. ETB is seen in high density in airway smooth
muscle and lower levels in lung parenchyma and airway submucosal
glands.
The results of our experiments on PEA specimens have shown that
both receptors are expressed with more expression of ETA receptors
comparedwith ETB. This would ﬁt with the size of our cross-sections in-
dicating that they are conduit artery sizewhere ETA expression has been
shown to be greater. The level of ETB expression we have found is with-
out question less than ETA but in some specimens seemed greater than
one might predict given data from congenital heart disease and idio-
pathic pulmonary arterial hypertension patients. Bauer et al. [3] have
shown, in addition to elevated circulating plasma big ET-1 levels, ele-
vated levels of ETB mRNA with no change in ETA mRNA in CTEPH spec-
imens suggesting ETB is upregulated.
Some similarities are thought to exist in the vascular remodelling
seen both in CTEPH to those observed in IPAH [21]. The implication of
this on our ﬁndings is that ET receptors will also be present in smaller
surgically inaccessible vessel obstructions hence ET receptor antago-
nists might have some effect on the SMCs in those obstructions. A
randomised placebo controlled trial of ET receptor antagonist in pa-
tients with inoperable chronic thromboembolic pulmonary hyperten-
sion and patients with persistent pulmonary hypertension after
pulmonary endarterectomy surgery [11] has shown statistically signiﬁ-
cant improvement in PVR and cardiac output but it is not possible to
know whether this was because of effects on the distal vasculopathy
or proximal obstructions described by the ‘two compartment model of
CTEPH’ [20].5. Conclusion
This study demonstrates the presence of functionally viable ET re-
ceptors in the surgically extracted tissue from patients with CTEPH.
The ET receptor was associated with smooth muscle cells, mainly the
contractile phenotype of SMC that surrounds the recanalised channels
and can be seen within the more organised chronic thrombus. Both
the ETA and ETB receptors were found with the ETA receptor showing
more expression. This shows a potential role for ET receptors to inﬂu-
ence both compartments in CTEPH and generates questions about
how ET antagonists might inﬂuence the pathological development of
the chronic thrombus in CTEPH.
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